An observational study in Huntington Disease, sponsored by BioSensics. Not yet recruiting at 2 sites in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by BioSensics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 32nd largest by planned enrollment of the 48 observational ones that give a count, is the only one that started in 2027, is one of 48 observational ones, reaches primary completion later than 19 of the 28 other live ones, and was the 134th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 90 across 82 observational studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
BioSensics is the lead sponsor of 12 studies on the registry; 8 are open to participants now.
BioSensics has 2 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD). Healthy subjects, as well as subjects with documented diagnosis of HD will be screened and recruited at University of Rochester Medical Center and Vanderbilt University Medical Center to participate in this 12-month observational study. There will be a total of 5 visits every approximately 3 months.
In each study visit, participants will complete several Patient Reported Outcomes (PROs), Clinical Reported Outcomes, complete a series of Digital Assessments (Speech, Cognitive, Motor, and Finger Tapping). Participants will be provided with a pendant, wrist, and ankle sensors to monitor their daily physical activities for 7 days after each study visit. Participants will also be provided with a tablet to complete digital assessments (Speech, Cognitive, Motor, and Finger Tapping) on monthly basis at home.
HD is a devastating inherited neurological disorder that causes progressive nerve degeneration in the brain. HD is characterized by multifaceted symptomatology including motor, cognitive, and psychiatric symptoms, which begin insidiously and progress over many years. The principal means of measuring gross motor and speech impairment in HD is the Unified Huntington's Disease Rating Scale (UHDRS). Although valuable, the scale is subjective and categorical and requires significant training to administer correctly. Quantitative motor (Q-motor) tests have helped reduce subjectivity and improve sensitivity of motor assessments in HD. Q-Motor assessments have demonstrated utility in tracking longitudinal progression of motor impairment and as a supplemental measure in clinical trials. Likewise, force-sensitive insoles, video motion analysis systems, and pressure-sensitive walking mats have been utilized to objectively measure impaired gait in HD. However, these gait-measuring technologies and Q-Motor assessments must be administered in clinic by trained personnel. Similarly, the Montreal Cognitive assessment (MoCA) and Mini-mental State Examination, are often used to measure cognitive decline. However, these tests need to be administered by trained professionals and have limited ability to detect subtle changes in cognitive performance over time. Furthermore, measures are conducted infrequently, typically in a clinic setting, and may not be an accurate representation of an individual's true cognitive status.
There is currently no cure which can halt, slow or reverse the progression of the disease. The key challenge in development of new therapeutics in HD and other neurological disorders is that the current way of assessing the disease is largely subjective and requires in-person, in-clinic assessments. Digital measures, like the proposed solution can provide objective, real-world assessments of how individuals are functioning.
Wearable sensors and digital health technologies that can detect motor, speech, and cognitive abnormalities can provide insight into the phase of clinical disease onset. Given that gene positive premanifest stage of HD can take up to several years before the onset of symptomatic disease, the subtle changes in these biomarkers in the early stage of HD provide an opportune window to apply disease-modifying treatment that could potentially slow down or prevent the progression of the disease
Thus, a system that can objectively, sensitively, and frequently monitor multiple clinical domains (motor, speech and cognitive function) is necessary to understand the pattern of evolving motor, speech and cognitive abnormalities in individuals with prodromal HD, and for identification of endpoint measures for therapeutic trials.
This observational study will follow participants over 12 months. Healthy subjects, as well as subjects with documented diagnosis of HD will be screened and recruited at University of Rochester Medical Center and Vanderbilt University Medical Center. In addition to standard clinical assessments, the study will leverage BioDigit HD to collect wearable and digital health data from participants in at the study site and their home environments.
A key objective of the project is to measure changes in disease symptoms using patient reported outcomes (PROs), clinical reported outcomes, and digital measures in individuals with HD.
Adults with clinical diagnosis of HD, and healthy age-matched controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For control participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with clinical diagnosis of HD
Age-matched healthy adults. Clinically assessed to be in good health, with no evidence of neurological disorders that could cause involuntary movements or gait disturbances.
Change in daily walking duration during activities of daily living from baseline to 12 months as measured by the PAMSys pendant
Daily walking duration (hours) will be measured by the PAMSys pendant. PAMSys is a FDA-listed Class II wearable device for measuring physical activity and posture during activities of daily living. PAMSys will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.
Time frame: 12 months
Change in daily number of sit to stand transitions (count) during activities of daily living from baseline to 12 months as measured by the PAMSys pendant.
Daily number of sit to stand transitions will be measured by the PAMSys pendant. PAMSys is a FDA-listed Class II wearable device for measuring physical activity and posture during activities of daily living. PAMSys will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.
Time frame: 12 months
Change in scores of Unified Huntington's Disease Rating Scale (UHDRS) from baseline to 12 months
A clinical tool used to assess motor, cognitive, and behavioral symptoms in individuals with Huntington's disease (HD). There are 5 parts to UHDRS 1. Total Motor Score: Scores range from 0 to 124. Higher scores represent a worse outcome. 2. Total Functional Capacity: Scores range from 0 to 13. Lower scores represent a worse outcome. 3. Behavioral Assessment: Scores range from 0 to 88. Higher scores represent a worse outcome. 4. Cognitive Assessments: Inclues Stroop test, Verbal Fluency, and Symbol Digit Modalities Test. Lower scores represent a worse outcome.
Time frame: 12 months
Change in intelligibility when reading a standard Rainbow passage from baseline to 12 months as measured by BioDigit Speech
Speech data will be collected from participants while reading a standard Rainbow passage on a monthly basis for 12 months. BioDigit Speech, and automatic speech analysis software, will be used to analyze the collected speech data to calculate intelligibility of speech during reading a standard Rainbow passage.
Time frame: 12 months
Change in walking speed during activities of daily living from baseline to 12 months as measured by the PAMSys Ankle sensor
median, 90 percentile and 96 percentile stride velocity (m/s) will be measured by the PAMSys Ankle sensor. PAMSys Ankle sensor will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.
Time frame: 12 months
Change in cadence during activities of daily living from baseline to 12 months as measured by the PAMSys pendant
Median, 90 percentile and 96 percentile cadence (steps/min) will be measured by the PAMSys pendant. PAMSys pendant will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.
Time frame: 12 months
Change in the Montreal Cognitive assessment (MoCA) score
The MoCA will be assessed from participants during baseline, 3 month, 6 month, 9 month and 12 month visits.
Time frame: 12 months
Change in tapping rate (number of taps per minute) from baseline to 12 months as measured by the BioDigit Clinic and BioDigit Home tablets
Finger tapping test will be collected from participants on a monthly basis for 12 months.
Time frame: 12 months
Change in daily number of hand goal-directed movements during activities of daily living from baseline to 12 months as measured by the PAMSys ULM wrist sensor
PAMSys ULM wrist sensor measures goal directed movements of the hand during activities of daily living. PAMSys ULM wrist sensors will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.
Time frame: 12 months
Change in the Verbal Fluency test score
Verbal fluency test data will be collected at baseline, 3 month, 6 month, 9 month and 12 month visits.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.
Of 34 observational studies under Huntington Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34. This study's planned 19 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jan 2027, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.